Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B.

Vögtle T, Sharma S, Mori J, Nagy Z, Semeniak D, Scandola C, Geer MJ, Smith CW, Lane J, Pollack S, Lassila R, Jouppila A, Barr AJ, Ogg DJ, Howard TD, McMiken HJ, Warwicker J, Geh C, Rowlinson R, Abbott WM, Eckly A, Schulze H, Wright GJ, Mazharian A, Fütterer K, Rajesh S, Douglas MR, Senis YA.

Elife. 2019 Aug 22;8. pii: e46840. doi: 10.7554/eLife.46840.

2.

Introduction of a C-terminal hexa-lysine tag increases thermal stability of the LacDiNac binding adhesin (LabA) exodomain from Helicobacter pylori.

Paraskevopoulou V, Artiaga VG, Rowlinson R, Winkler GS, Gellert P, Stolnik S, Overman R, Falcone FH.

Protein Expr Purif. 2019 Nov;163:105446. doi: 10.1016/j.pep.2019.105446. Epub 2019 Jul 1.

3.

Rapid isolation and enrichment of extracellular vesicle preparations using anion exchange chromatography.

Heath N, Grant L, De Oliveira TM, Rowlinson R, Osteikoetxea X, Dekker N, Overman R.

Sci Rep. 2018 Apr 10;8(1):5730. doi: 10.1038/s41598-018-24163-y.

4.

Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells.

Trinidad AG, Whalley N, Rowlinson R, Delpuech O, Dudley P, Rooney C, Critchlow SE.

Oncogene. 2017 Nov 2;36(44):6164-6176. doi: 10.1038/onc.2017.224. Epub 2017 Jul 10.

5.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

Weir HM, Bradbury RH, Lawson M, Rabow AA, Buttar D, Callis RJ, Curwen JO, de Almeida C, Ballard P, Hulse M, Donald CS, Feron LJ, Karoutchi G, MacFaul P, Moss T, Norman RA, Pearson SE, Tonge M, Davies G, Walker GE, Wilson Z, Rowlinson R, Powell S, Sadler C, Richmond G, Ladd B, Pazolli E, Mazzola AM, D'Cruz C, De Savi C.

Cancer Res. 2016 Jun 1;76(11):3307-18. doi: 10.1158/0008-5472.CAN-15-2357. Epub 2016 Mar 28.

6.

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Ashford AL, Dunkley TP, Cockerill M, Rowlinson RA, Baak LM, Gallo R, Balmanno K, Goodwin LM, Ward RA, Lochhead PA, Guichard S, Hudson K, Cook SJ.

Cell Mol Life Sci. 2016 Feb;73(4):883-900. doi: 10.1007/s00018-015-2032-x. Epub 2015 Sep 7.

7.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

8.

Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation.

Waring MJ, Andrews DM, Faulder PF, Flemington V, McKelvie JC, Maman S, Preston M, Raubo P, Robb GR, Roberts K, Rowlinson R, Smith JM, Swarbrick ME, Treinies I, Winter JJ, Wood RJ.

Chem Commun (Camb). 2014 May 25;50(40):5388-90. doi: 10.1039/c3cc48391f. Epub 2013 Dec 24.

PMID:
24366037
9.

Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours.

Milner R, Wombwell H, Eckersley S, Barnes D, Warwicker J, Van Dorp E, Rowlinson R, Dearden S, Hughes G, Harbron C, Wellings B, Hodgson D, Womack C, Gray N, Lau A, O'Connor MJ, Marsden C, Kvist AJ.

Virchows Arch. 2013 Mar;462(3):269-79. doi: 10.1007/s00428-012-1368-y. Epub 2013 Jan 25. Erratum in: Virchows Arch. 2013 May;462(5):601. Rowlinson, Rachel [added].

PMID:
23354597
10.

Characterization of renal papillary antigen 1 (RPA-1), a biomarker of renal papillary necrosis.

Price SA, Davies D, Rowlinson R, Copley CG, Roche A, Falkenberg FW, Riccardi D, Betton GR.

Toxicol Pathol. 2010 Apr;38(3):346-58. doi: 10.1177/0192623310362246. Epub 2010 Mar 16.

PMID:
20233945
11.

Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice.

Rantalainen M, Cloarec O, Beckonert O, Wilson ID, Jackson D, Tonge R, Rowlinson R, Rayner S, Nickson J, Wilkinson RW, Mills JD, Trygg J, Nicholson JK, Holmes E.

J Proteome Res. 2006 Oct;5(10):2642-55.

PMID:
17022635
12.

Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat.

Craig A, Sidaway J, Holmes E, Orton T, Jackson D, Rowlinson R, Nickson J, Tonge R, Wilson I, Nicholson J.

J Proteome Res. 2006 Jul;5(7):1586-601.

PMID:
16823966
13.

Prostatic tissue protein alterations due to delayed time to freezing.

Jackson D, Rowlinson RA, Eaton CK, Nickson JA, Wilson ID, Mills JD, Wilkinson RW, Tonge RP.

Proteomics. 2006 Jul;6(13):3901-8.

PMID:
16767789
14.

Development of a high-throughput method for preparing human urine for two-dimensional electrophoresis.

Smith G, Barratt D, Rowlinson R, Nickson J, Tonge R.

Proteomics. 2005 Jun;5(9):2315-8.

PMID:
15887186
15.

Evaluation of saturation labelling two-dimensional difference gel electrophoresis fluorescent dyes.

Shaw J, Rowlinson R, Nickson J, Stone T, Sweet A, Williams K, Tonge R.

Proteomics. 2003 Jul;3(7):1181-95.

PMID:
12872219
16.

Quantitative proteomic analysis of mouse liver response to the peroxisome proliferator diethylhexylphthalate (DEHP).

Macdonald N, Chevalier S, Tonge R, Davison M, Rowlinson R, Young J, Rayner S, Roberts R.

Arch Toxicol. 2001 Sep;75(7):415-24.

PMID:
11693183
17.

Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology.

Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M.

Proteomics. 2001 Mar;1(3):377-96.

PMID:
11680884
18.

Proteomic analysis of differential protein expression in primary hepatocytes induced by EGF, tumour necrosis factor alpha or the peroxisome proliferator nafenopin.

Chevalier S, Macdonald N, Tonge R, Rayner S, Rowlinson R, Shaw J, Young J, Davison M, Roberts RA.

Eur J Biochem. 2000 Aug;267(15):4624-34.

19.

Supplemental Content

Loading ...
Support Center